Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RB1 |
Variant | mutant |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | RB1 mutant indicates an unspecified mutation in the RB1 gene. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05933395 | Phase II | Abemaciclib + Fulvestrant Fulvestrant + Neratinib Alpelisib + Fulvestrant Everolimus + Fulvestrant | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (GERTRUDE) | Recruiting | USA | 0 |
NCT04391595 | Phase I | Abemaciclib + LY3214996 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | Recruiting | USA | 0 |
NCT03434262 | Phase I | Ribociclib + Trametinib Filgrastim + Gemcitabine + Ribociclib Ribociclib + Sonidegib | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | Completed | USA | 0 |
NCT05986071 | Phase Ib/II | Fulvestrant + M1774 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) | Not yet recruiting | FRA | 0 |
NCT03834740 | Phase I | Everolimus + Ribociclib | A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection | Completed | USA | 0 |
NCT05696626 | Phase III | Abemaciclib + Fulvestrant Abemaciclib + Lasofoxifene | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 3 |
NCT05940493 | Phase II | Abemaciclib | Abemaciclib in Newly Diagnosed Meningioma Patients | Not yet recruiting | USA | 0 |
NCT04388852 | Phase I | DS-3201b + Ipilimumab | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Recruiting | USA | 0 |
NCT04129151 | Phase II | Ganitumab + Palbociclib | Palbociclib + Ganitumab In Ewing Sarcoma | Terminated | USA | 0 |
NCT04412629 | Phase II | Cabozantinib | Cabozantinib in High Grade Neuroendocrine Neoplasms | Recruiting | USA | 0 |
NCT05673811 | Phase II | Gemcitabine + Nab-paclitaxel + VCN-01 Gemcitabine + Nab-paclitaxel | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer (VIRAGE) | Active, not recruiting | USA | ESP | 0 |
NCT04592237 | Phase II | Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03567642 | Phase I | Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib | A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers | Active, not recruiting | USA | 0 |
NCT06515470 | Phase I | BTX-9341 BTX-9341 + Fulvestrant | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer | Recruiting | USA | 0 |